The overall goal of the Florida A&M University (FAMU) Research Centers in Minority Institutions (RCMI) Pharmaceutical Research Center (PRC) application (2013-2018) is to continue the development of its infrastructure and increase the number and skill proficiency of minority scientists engaged in advanced biomedical research (breast, lung, and prostate cancers, infectious and neurodegenerative). These goals will be accomplished through the establishment of three synergistic research resources cores, with services to enable investigative research on specific pathological etiologies associated with health inequity amongst minority groups, especially African-Americans. The PRC is to be supported by enrichment programs administered through the main RCMI Research Program Administration (RPA) Core. The RPA will provide (Faculty Development Program) multi-administrative assistance, grants support, foster faculty development through workshops, seminars, and skill specific trainings;(Pilot Projects Program) provide novel projects with financial support, and structured mentoring;(Research Collaboration Program) that will organize, identify and orchestrate effective internal and external multidisciplinary collaborations utilizing RTRN/ RTRN eagle-i, all of which will be optimized through ongoing performance evaluation. The Evaluation Plan (EP) will optimize RCMI program success in achieving its goals and objectives, with summative and formative evaluation using state-of-the-art information technology and communications webbased platforms for organization and tracking of performance data. The EP will identify challenges, ineffective use of resources;ensure achievement of milestones;and provide ongoing guidance toward corrective actions. The RRC will serve to promote greater participation of minority scientists in practical applications of rapdly evolving areas of biomedical research, drug development, genetics, and epigenetic research with a focus on maladaptive phenotypic changes evoked by environmental factors inherent to disadvantaged population groups. The RRC includes a: (1) Biotechnology Research Investigational Core providing services in proteomics;(peptide sequencing, protein identification, post translational modifications), flow cytometry, imaging, high throughput screening and other advanced biomedical applications;(2) Drug Discovery Core providing services for novel drug development, also a contribution to translational research, including NMR, FT IR, UV, LC/GC-Mass Spectrum, HPLC, and computer-based molecular modeling;and (3) Molecular Genetics Core will provide a) Gene and Cell Manipulation Facility, b) Epigenetics, and c) Microarray Facilities providing diverse services in gene cloning, constructs for knock-downs, -outs and -ins, stable transfectants, DNA sequencing, methylation, histone modifications;chromatin biochemistry, RNA analysis, sequencing and synthesis, and microarray services for global expression profiling. The RPA will Recruit and Hire a Scientist for a position as an Associate Professor in molecular genetics (as a component to the Molecular Genetics Core) to enhance faculty and staff proficiency. The funding of FAMU RCMI program is relevant to the State of Florida and specifically, the nation as it seeks to increase the number of minority research investigators, thereby, improving the education and research effectiveness in addressing health care issues affecting minorities and African American communities. These efforts will result in positive health outcomes in addition to decreasing and eliminating health disparities.
The FAMU RCMI PRC goal is to strengthen and support research infrastructure at Florida A&M University which ultimately will benefit the health and well-being of racial and ethnic minority populations. The theme of the Center is One team-One goal, benefiting the health of minorities.
|Mochona, Bereket; Qi, Xin; Euynni, Suresh et al. (2016) Design and evaluation of novel oxadiazole derivatives as potential prostate cancer agents. Bioorg Med Chem Lett 26:2847-51|
|Zarmouh, Najla O; Messeha, Samia S; Elshami, Faisel M et al. (2016) Evaluation of the Isoflavone Genistein as Reversible Human Monoamine Oxidase-A and -B Inhibitor. Evid Based Complement Alternat Med 2016:1423052|
|Diaby, Vakaramoko; Adunlin, Georges; Ali, Askal A et al. (2016) Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States. Breast Cancer Res Treat 160:187-196|
|Odewumi, Caroline O; Latinwo, Lekan M; Ruden, Michael L et al. (2016) Modulation of cytokines and chemokines expression by NAC in cadmium chloride treated human lung cells. Environ Toxicol 31:1612-1619|
|Diaby, Vakaramoko; Ali, Askal A; Adunlin, Georges et al. (2016) Parameterization of a disease progression simulation model for sequentially treated metastatic human epidermal growth factor receptor 2 positive breast cancer patients. Curr Med Res Opin 32:991-6|
|Cobourne-Duval, Makini K; Taka, Equar; Mendonca, Patricia et al. (2016) The Antioxidant Effects of Thymoquinone in Activated BV-2 Murine Microglial Cells. Neurochem Res 41:3227-3238|
|Tawk, Rima; Abner, Adrian; Ashford, Alicestine et al. (2016) Differences in Colorectal Cancer Outcomes by Race and Insurance. Int J Environ Res Public Health 13:ijerph13010048|
|Williams, Marlon D; Nguyen, Thu; Carriere, Patrick P et al. (2016) Protein Kinase CK2 Expression Predicts Relapse Survival in ERÎ± Dependent Breast Cancer, and Modulates ERÎ± Expression in Vitro. Int J Environ Res Public Health 13:ijerph13010036|
|Williams, Henry N; Lymperopoulou, Despoina S; Athar, Rana et al. (2016) Halobacteriovorax, an underestimated predator on bacteria: potential impact relative to viruses on bacterial mortality. ISME J 10:491-9|
|Mazzio, Elizabeth A; Li, Nan; Bauer, David et al. (2016) Natural product HTP screening for antibacterial (E.coli 0157:H7) and anti-inflammatory agents in (LPS from E. coli O111:B4) activated macrophages and microglial cells; focus on sepsis. BMC Complement Altern Med 16:467|
Showing the most recent 10 out of 123 publications